Updates on Tafasitamab for the Treatment of DLBCL

DSF/Cu Induces Antitumor Effect Against DLBCL Through Suppressing NF-κB/BCL6 Pathways

The Antibody-Drug Conjugate Loncastuximab Tesirine for the Treatment of DLBCL

Pola-R-CHP May Be Cost Effective, Depending on PFS Outcomes in Previously Untreated DLBCL

A Rare Case of DLBCL Presenting as a Malignant Mass in Both Duodenum and Ascending Colon

What Are the Key Considerations for CAR T-Cell Therapy in Elderly Patients With Lymphoma?

Glofitamab Induces Durable Complete Remissions in Patients With Relapsed Large B-Cell Lymphoma

Updates on Tafasitamab for the Treatment of DLBCL

header-info

Aug, 05, 2022

In this video, Wojciech Jurczak, MD, PhD, Jagiellonian University, Krakow, Poland, talks on tafasitamab for the treatment of diffuse large B-cell lymphoma (DLBCL), highlighting a study which demonstrated the efficacy of patients treated with tafasitamab plus lenalidomide compared to patients treated with polatuzumab vedotin and CAR-T cell therapy.